台灣臨床試驗主持人資料庫|TPIDB

問卷

Log In

繁中 EN

TPIDB

TPIDB Outstanding PI

TPIDB > Study Site > 收納受試者人數排名

Search Result

List

5Cases

2014-10-09 - 2018-12-31

Phase III

Confirmatory Study of DSP-5423P in Patients with Schizophrenia <Phase 3>

Condition/Disease

Schizophrenia
Test Drug

DSP-5423P

Participate Sites
6Sites

Terminated6Sites

黃宗正

National Taiwan University Hospital

2010-09-01 - 2012-12-31

Phase III

A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo in subjects with an acute exacerbation of schizophrenia (Phase 3 ; Protocol No. P06124)

Condition/Disease

Schizophrenia
Test Drug

Asenapine (SCH 900274)

Participate Sites
13Sites

Terminated13Sites

黃宗正

National Taiwan University Hospital

Division of Psychiatry

2012-09-01 - 2016-02-28

Phase III

Long-term Extension Study of SM-13496 (lurasidone HCl) in Patients with Schizophrenia <Phase 3>

Condition/Disease

Schizophrenia
Test Drug

SM-13496

Participate Sites
8Sites

Terminated8Sites

黃宗正

National Taiwan University Hospital

Division of Psychiatry

2012-08-01 - 2015-08-31

Phase III

Randomized, Double-blind, Parallel- group, Placebo-controlled, Confirmatory Study of SM-13496 (lurasidone HCl) in Patients with Schizophrenia <Phase 3>

Condition/Disease

schizophrenia
Test Drug

SM-13496

Participate Sites
13Sites

Terminated13Sites

黃宗正

National Taiwan University Hospital

Division of Psychiatry

2018-05-04 - 2020-12-31

Phase II

A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over 12 week treatment period in patients with Schizophrenia

Condition/Disease

Patients with established Schizophrenia (as per DSM-5) who are clinically stable
Test Drug

BI 425809

Participate Sites
4Sites

Terminated4Sites

黃宗正

National Taiwan University Hospital

Division of Psychiatry